STAT

SEPTEMBER 24, 2024

Generate:Biomedicines, a Flagship Pioneering company using artificial intelligence to create new medicines, announced today that it has struck a deal with Novartis to develop an undisclosed number of targets in various disease areas. With milestone payments, the company is eligible to receive over $1 billion, in addition to royalties.

Drug Development 222

Drug Development 222

STAT

AUGUST 22, 2024

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and potentially harms — the billions of people of color on the planet.

Drug Development 237

Drug Development 237

PharmaVoice

OCTOBER 15, 2024

A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.

Drug Development 289

Drug Development 289

STAT

OCTOBER 29, 2024

based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based

Drug Development 264

Drug Development 264

STAT

OCTOBER 9, 2024

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs.

Drug Development 240

Drug Development 240

STAT

SEPTEMBER 8, 2023

But in recent years, progress in the world of ALS research and drug development has come to embody a conundrum with far broader implications: The balance between moving aggressively on promising new cures and guarding against false hope. A diagnosis of ALS has long been seen as a death sentence. Read the rest…

Drug Development 314

Drug Development 314

STAT

AUGUST 19, 2024

And the startup was based in Salt Lake City, Utah — an area better known for its ski slopes and connection to the Church of Jesus Christ of Latter-day Saints than drug development.      Continue to STAT+ to read the full story…

Medical Schools 345

Medical Schools Drug Development Pharmaceutical Companies Pharmaceutical Companies 345

PharmaVoice

JUNE 30, 2022

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

Drug Development 336

Drug Development 336

STAT

MAY 20, 2024

But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing. Artificial intelligence is a rapidly improving technology. To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets.

Drug Development 321

Drug Development 321

PharmaVoice

OCTOBER 25, 2023

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

Drug Development 321

Drug Development 321

STAT

APRIL 22, 2024

And how much dystrophin he has in his body depends on the ability of drug developers to continue improving it with innovation. In its absence, the house of cards comes down. For my 6-year-old son, Charlie, dystrophin will govern how long he lives. Read the rest…

Drug Development 275

Drug Development 275

STAT

MARCH 29, 2023

A growing shortage of monkeys used for early-stage pharmaceutical research is causing concern that many companies will soon face costly delays starting clinical trials — leading to a slowdown in drug development. In recent weeks, the U.S

Drug Development 300

Drug Development 300

STAT

SEPTEMBER 9, 2024

To be clear, I’m not writing this to claim credit for discovery or development of GLP-1s or anything like that. Rather, I think the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. Read the rest…

Drug Development 304

Drug Development Pharmaceutical Companies Pharmaceutical Companies 304

PharmaVoice

OCTOBER 11, 2023

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

Drug Development 290

Drug Development 290

STAT

OCTOBER 12, 2023

Peter Marks wants drug developers to ask more stupid questions.    It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances.

Drug Development 288

Drug Development 288

STAT

OCTOBER 16, 2023

People with obesity often go underrepresented in drug development trials, a critical gap that researchers say leaves drugmakers and doctors unsure of efficacy or risks in that patient population.

Drug Development 261

Drug Development 261

STAT

OCTOBER 31, 2023

Now, the companies say they have developed the model to predict not just standalone protein structures, but what proteins look like in combination with several classes of molecules, including small molecules and nucleic acids — capabilities that are key for drug development.

Drug Development 297

Drug Development 297

PharmaVoice

DECEMBER 22, 2023

Still, the complexities of the disease and of drug development have brought hard-felt losses. The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists.

Drug Development 264

Drug Development 264

STAT

JANUARY 30, 2024

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

Drug Development 255

Drug Development 255

STAT

SEPTEMBER 5, 2024

Pediatric cancer researchers hoping to advance care have had to rely largely on repurposing newer drugs developed for adults — a limited strategy, as pediatric malignancies often have unique biology that require unique drugs.    On Thursday, though, two U.K.

Chemotherapy 228

Chemotherapy Drug Development 228

STAT

JANUARY 17, 2024

Recursion, a biotechnology firm that uses machine learning for drug development and and which was announcing that it is rolling out AI-driven drug discovery software with tech giant Nvidia, decided to seize the moment. It was going to rain.

Drug Development 264

Drug Development 264

STAT

OCTOBER 25, 2023

The drug, called BIIB080, is being developed by Biogen. “We are very encouraged by the consistency of the data,” said Priya Singhal, Biogen’s chief of drug development, while also emphasizing the company is not trying to oversell the significance of the findings.

Drug Development 314

Drug Development 314

STAT

AUGUST 20, 2024

19 letter that the House China committee sent to the Food and Drug Administration.    The bipartisan inquiry jeopardizes yet another aspect of drug development for which drugmakers increasingly rely on China, where it’s cheaper.   “For over a decade, it appears that U.S.

Hospitals 288

Hospitals Drug Development 288

STAT

JULY 25, 2024

Many people were stunned when an FDA advisory committee voted “no” on a new drug application for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) earlier this summer. Several things were stacked against approval: The FDA greenlights only about 50 new drugs each year. I was not among them.

Compounding 285

Compounding Drug Development 285

STAT

OCTOBER 14, 2024

Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. But there’s one field that has seen an even more significant amount of activity: autoimmune diseases.

Immunity 301

Immunity Immunization Drug Development 301

STAT

OCTOBER 17, 2024

Likely more than in any other industry, patents are essential to incentivize R&D in biopharmaceuticals due to the extremely lengthy, costly, and risky nature of drug development.

Drug Development 264

Drug Development Pharmaceutical Companies Pharmaceutical Companies 264

STAT

MAY 22, 2024

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition. HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function.

Immunization 257

Immunization Immunity Drug Development 257

STAT

AUGUST 14, 2024

It’s also the latest attempt to deal with one of the biggest challenges in drug development: What should a company do when it wins big? But inventing a mega-blockbuster — in this case novel drugs that treat obesity and diabetes — brings its own set of issues. It’s a sizeable and conspicuous bet.

Diabetes 318

Diabetes Drug Development 318

STAT

SEPTEMBER 3, 2024

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer. 

Drug Development 254

Drug Development 254

STAT

AUGUST 8, 2024

” STAT’s Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1.

Drug Pricing 203

Drug Pricing Drug Development 203

STAT

JULY 12, 2024

Over the past decade, precision medicine has evolved from merely creating personalized treatment plans and delivery methods to being integral throughout the entire drug development process. A similar approach needs to be implemented at scale for clinical trials. Read the rest…

Drug Development 203

Drug Development 203

STAT

SEPTEMBER 20, 2024

The Food and Drug Administration on Friday approved the first treatment for Niemann-Pick disease, type C, the culmination of years of advocacy and stutter-start drug development efforts in the rare neurological condition.

Drug Development 189

Drug Development 189

STAT

SEPTEMBER 5, 2024

We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.

Drug Development 212

Drug Development 212

STAT

JULY 25, 2024

The reorganization comes at a time when industry — from medical device makers to drug developers to health IT vendors — are itching to influence developing technology regulation, in particular for AI.

Drug Development 262

Drug Development 262

STAT

JUNE 27, 2024

STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.   Read the rest…

Drug Development 212

Drug Development 212

STAT

SEPTEMBER 12, 2024

patient information is a national security concern, as is the overreliance on China for drug development. BIOSECURE proponents argue that allowing the Chinese Communist Party access to U.S. They aren’t wrong. Protecting that information and being able to make our own medicines should be a national priority.

Pharmaceutical Companies 245

Pharmaceutical Companies Pharmaceutical Companies Drug Development 245

STAT

SEPTEMBER 4, 2024

This type of treatment has become a hot spot in drug development, leading to several acquisitions over the last year.    Novartis is the leading producer of radiopharmaceutical or radioligand therapies, an emerging type of cancer treatment in which a potent dose of radioactive molecules is dispatched to harm cancer cells.

Drug Development 208

Drug Development 208